Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

AstraZeneca Acquires Obesity Startup SixPeaks Bio for $170 Million

AstraZeneca Acquires Obesity Startup SixPeaks Bio for $170 Million

AstraZeneca has exercised its option to acquire SixPeaks Bio, a weight loss-focused startup, for $170 million upfront. The deal, disclosed in AstraZeneca's latest quarterly earnings report, marks a significant move in the pharmaceutical giant's strategy to expand its presence in the competitive obesity drug market.

NoahAI News11/7/2025
AstraZeneca Shifts Focus in Obesity Drug Development, Emphasizing Medical Benefits Over Aesthetics

AstraZeneca Shifts Focus in Obesity Drug Development, Emphasizing Medical Benefits Over Aesthetics

AstraZeneca, one of the world's leading pharmaceutical companies, is carving out a distinct niche in the increasingly competitive obesity drug market. CEO Pascal Soriot revealed the company's strategy during a recent investor call, highlighting a focus on the medical aspects of weight loss rather than aesthetic outcomes.

NoahAI News11/7/2025
FDA Leadership Shakeup Continues as CDER Directorship Remains Vacant

FDA Leadership Shakeup Continues as CDER Directorship Remains Vacant

The U.S. Food and Drug Administration (FDA) faces ongoing leadership challenges as the search for a new director of the Center for Drug Evaluation and Research (CDER) continues. This development comes in the wake of recent high-profile departures and amid broader changes at the Department of Health and Human Services (HHS).

NoahAI News11/7/2025
Bidding War Intensifies as Novo Nordisk Challenges Pfizer's Acquisition of Metsera

Bidding War Intensifies as Novo Nordisk Challenges Pfizer's Acquisition of Metsera

In a stunning turn of events, Novo Nordisk has launched an unsolicited bid to acquire obesity drug developer Metsera, challenging Pfizer's previously announced acquisition agreement. The move has sparked a high-stakes bidding war between two pharmaceutical giants, with potential implications for the future of obesity treatment and antitrust concerns in the industry.

NoahAI News11/7/2025
FTC Scrutiny and Bidding War: Novo Nordisk and Pfizer Compete for Metsera Acquisition

FTC Scrutiny and Bidding War: Novo Nordisk and Pfizer Compete for Metsera Acquisition

In a high-stakes bidding war that has captured the attention of the pharmaceutical industry, Novo Nordisk and Pfizer are vying for control of obesity biotech Metsera. The competition has intensified, with both companies increasing their offers and the Federal Trade Commission (FTC) raising concerns about potential antitrust violations.

NoahAI News11/7/2025
Cullinan Therapeutics Refocuses Pipeline, Discontinues Oncology Programs Amid Autoimmune Push

Cullinan Therapeutics Refocuses Pipeline, Discontinues Oncology Programs Amid Autoimmune Push

Cullinan Therapeutics, formerly known as Cullinan Oncology, has announced a significant shift in its research and development strategy, discontinuing two oncology programs while reinforcing its commitment to autoimmune diseases and T cell engagers. The move marks a pivotal moment in the company's evolution, balancing its pipeline between autoimmune and cancer indications.

NoahAI News11/7/2025
Moderna's Cost-Cutting Measures Show Promise Amid Declining Vaccine Sales

Moderna's Cost-Cutting Measures Show Promise Amid Declining Vaccine Sales

Moderna, the biotech giant that rose to prominence during the COVID-19 pandemic, is navigating a challenging landscape as vaccine sales continue to decline. Despite this setback, the company's aggressive cost-cutting strategy and pipeline developments are showing signs of promise, potentially paving the way for financial stability in the coming years.

NoahAI News11/7/2025
Bavarian Nordic Buyout Bid Fails, Company to Remain Independent

Bavarian Nordic Buyout Bid Fails, Company to Remain Independent

Bavarian Nordic, the Danish vaccine maker, will continue as an independent entity after a proposed private equity buyout failed to secure sufficient shareholder support. The offer, made by Nordic Capital and Permira through a newly formed company called Innosera, fell short of the required 66.7% shareholder acceptance, garnering only 60% approval by the November 5 deadline.

NoahAI News11/7/2025
J&J's Caplyta Gains FDA Approval for Major Depressive Disorder, Bolstering $5 Billion Sales Ambition

J&J's Caplyta Gains FDA Approval for Major Depressive Disorder, Bolstering $5 Billion Sales Ambition

Johnson & Johnson (J&J) has secured a significant victory in its neuroscience portfolio as the U.S. Food and Drug Administration (FDA) approved the expanded use of Caplyta for patients with major depressive disorder. This latest development marks a crucial step in J&J's strategy to position Caplyta as a blockbuster drug with potential annual sales of $5 billion.

NoahAI News11/7/2025
Axsome Therapeutics Acquires AstraZeneca's Epilepsy Candidate in $83 Million Deal

Axsome Therapeutics Acquires AstraZeneca's Epilepsy Candidate in $83 Million Deal

Axsome Therapeutics has made a significant move in the epilepsy treatment space, acquiring AstraZeneca's phase 2 oral GABA receptor modulator through a subsidiary acquisition. The deal, potentially worth over $83 million, marks Axsome's entry into the epilepsy market and bolsters its central nervous system (CNS) portfolio.

NoahAI News11/7/2025
UroGen Terminates Anti-CTLA-4 Partnership with Agenus Following Disappointing Phase 1 Results

UroGen Terminates Anti-CTLA-4 Partnership with Agenus Following Disappointing Phase 1 Results

In a significant setback for both companies, UroGen Pharmaceuticals has announced the termination of its license agreement with Agenus for the development of zalifrelimab (UGN-301), an anti-CTLA-4 antibody intended for the treatment of urinary tract cancers. The decision comes after phase 1 data failed to meet UroGen's internal benchmarks for advancement to phase 2 trials.

NoahAI News11/7/2025
Cigna Reshuffles Executive Leadership Amidst Industry Challenges

Cigna Reshuffles Executive Leadership Amidst Industry Challenges

Cigna, one of the largest health insurance providers in the United States, has announced significant changes to its executive leadership team. These moves come as the company, along with the broader healthcare industry, faces increasing scrutiny over rising costs and consumer dissatisfaction.

NoahAI News11/7/2025
«1234...67»